MaaT Pharma SA (EPA:MAAT)

Market Cap	55.21M -29.4%
Revenue (ttm)	4.52M +40.7%
Net Income	-31.06M
EPS	-1.95
Shares Out	18.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,242
Open	2.860
Previous Close	2.855
Day's Range	2.860 - 3.020
52-Week Range	2.600 - 8.620
Beta	0.46
Analysts	Buy
Price Target	10.00 (+241.3%)
Earnings Date	Sep 29, 2026

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 59
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2025, MaaT Pharma's revenue was 4.52 million, an increase of 40.67% compared to the previous year's 3.22 million. Losses were -31.06 million, 7.46% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for MAAT stock is "Buy." The 12-month stock price target is €10.00, which is an increase of 241.30% from the latest price.

Price Target

€10.00

(241.30% upside)

Analyst Consensus: Buy